SEC Form 4 · accession 0001140361-15-004201

SANGAMO THERAPEUTICS, INC · SGMO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP of Research & CSO

Period of report

Feb 2, 2015

Accepted (ET)

Feb 4, 2015 · 7:31 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001001233

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1	Feb 2, 2015	M	3,000	$3.45	A	119,410	D
Common Stock^F1	Feb 2, 2015	M	5,000	$5.35	A	124,410	D
Common Stock^F1	Feb 2, 2015	M	7,000	$5.70	A	131,410	D
Common Stock^F3,F1	Feb 2, 2015	S	15,000	$12.8553	D	116,410	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F4	$3.45	Feb 2, 2015	M	3,000	D	—	Dec 9, 2018	Common Stock	3,000	28,500	D
Employee Stock Option (Right to Buy)^F4	$5.35	Feb 2, 2015	M	5,000	D	—	Dec 6, 2019	Common Stock	5,000	40,000	D
Employee Stock Option (Right to Buy)^F4	$5.70	Feb 2, 2015	M	7,000	D	—	Dec 7, 2020	Common Stock	7,000	48,172	D

F1Includes 13,333, 23,333 and 37,500 shares subject to RSUs granted on December 6, 2012, December 12, 2013 and December 11, 2014 respectively, which will be issued as such units vest in accordance with their terms.
F2The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2014.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.82 to $12.86, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F4All shares underlying this option are vested and immediately exercisable.